Aberrant glycogen synthase kinase 3β in the development of pancreatic cancer
| Autor: | Yoshiharu Motoo, Takeo Shimasaki, Toshinari Minamoto, Ayako Kitano |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2012 |
| Předmět: |
Cancer Research
Carcinogenesis Health Toxicology and Mutagenesis medicine.medical_treatment pancreatic cancer tumor progression Review Article medicine.disease_cause lcsh:RC254-282 GSK-3 Pancreatic cancer medicine Protein kinase A business.industry Cancer GSK3β medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Gemcitabine Radiation therapy Oncology Tumor progression Immunology Cancer research business medicine.drug |
| Zdroj: | Journal of Carcinogenesis, Vol 11, Iss 1, Pp 15-15 (2012) Journal of Carcinogenesis |
| ISSN: | 1477-3163 |
| Popis: | Development and progression of pancreatic cancer involves general metabolic disorder, local chronic inflammation, and multistep activation of distinct oncogenic molecular pathways. These pathologic processes result in a highly invasive and metastatic tumor phenotype that is a major obstacle to curative surgical intervention, infusional gemcitabine-based chemotherapy, and radiation therapy. Many clinical trials with chemical compounds and therapeutic antibodies targeting growth factors, angiogenic factors, and matrix metalloproteinases have failed to demonstrate definitive therapeutic benefits to refractory pancreatic cancer patients. Glycogen synthase kinase 3β (GSK3β), a serine/threonine protein kinase, has emerged as a therapeutic target in common chronic and progressive diseases, including cancer. Here we review accumulating evidence for a pathologic role of GSK3β in promoting tumor cell survival, proliferation, invasion, and resistance to chemotherapy and radiation in pancreatic cancer. We also discuss the putative involvement of GSK3β in mediating metabolic disorder, local inflammation, and molecular alteration leading to pancreatic cancer development. Taken together, we highlight potential therapeutic as well as preventive effects of GSK3β inhibition in pancreatic cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|